Are there any ways around the exposure-limiting nephrotoxicity of the polymyxins?

International Journal of Antimicrobial Agents

Volumn 48, Issue 6, 2016, Pages 622-626

  Pogue, Jason M ^a,b   Ortwine, Jessica K ^c,d   Kaye, Keith S ^b,e  

^a SINAI GRACE HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PARKLAND HEALTH AND HOSPITAL SYSTEM   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e DETROIT MEDICAL CENTER   (United States)

Author keywords

Acute kidney injury; Colistin; Multidrug resistant; Nephrotoxicity; Polymyxin B

Indexed keywords

COLISTIN; POLYMYXIN B; ANTIINFECTIVE AGENT; POLYMYXIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; DOSE RESPONSE; DRUG EXPOSURE; DRUG RESEARCH; ENTEROBACTERIACEAE; HUMAN; NEPHROTOXICITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RISK FACTOR; ACUTE KIDNEY FAILURE; DRUG EFFECTS; KIDNEY; RISK MANAGEMENT;

ACUTE KIDNEY INJURY; ANTI-BACTERIAL AGENTS; HUMANS; KIDNEY; POLYMYXINS; RISK FACTORS; RISK MANAGEMENT;

EID: 85000997421     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.11.001     Document Type: Article

References (37)

1. [1] Stansly, P.G., Shepherd, R.G., White, H.J., Polymyxin: a new chemotherapeutic agent. Bull Johns Hopkins Hosp 81 (1947), 43–54.
2. [2] Brownlee, G., Jones, T.S., The polymyxins: a related series of antibiotics derived from B. polymyxa. Biochem J, 43, 1948, 25.
3. [3] Pulaski, E.J., Baker, H.J., Rosenberg, M.L., Connell, J.F., Laboratory and clinical studies of polymyxin B and E. J Clin Invest 28 (1949), 1028–1031.
4. [4] Elwood, C.M., Lucas, G.D., Acute renal failure associated with sodium colistimethate treatment. Arch Intern Med 118 (1966), 326–334.
5. [5] Koch-Weser, J., Sidel, V.W., Federman, E.B., Kanarek, P., Finer, D.C., Eaton, A.E., Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 72 (1970), 857–868.
6. [6] Levin, A.S., Barone, A.A., Penço, J., Santos, M.V., Marinho, I.S., Arruda, E.A., et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 28 (1999), 1008–1011.
7. [7] Petersdorf, R.G., Plorde, J.J., Colistin—a reappraisal. JAMA 183 (1963), 123–125.
8. [8] Ledson, M.J., Gallagher, M.J., Cowperthwaite, C., Convery, R.P., Walshaw, M.J., Four years' experience of intravenous colomycin in an adult cystic fibrosis unit. Eur Respir J 12 (1998), 592–594.
9. [9] Conway, S.P., Pond, M.N., Watson, A., Etherington, C., Robey, H.L., Goldman, M.H., Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 52 (1997), 987–993.
10. [10] Littlewood, J.M., Miller, M.G., Ghoneim, A.T., Ramsden, C.H., Nebulised colomycin for early Pseudomonas colonisation in cystic fibrosis. Lancet, 1, 1985, 865.
11. [11] Nordmann, P., Naas, T., Poirel, L., Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17 (2011), 1791–1798.
12. [12] Rigatto, M.H., Behle, T.F., Falci, D.R., Freitas, T., Lopes, N.T., Nunes, M., et al. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. J Antimicrob Chemother 70 (2015), 1552–1557.
13. [13] Balkan, I.I., Dogan, M., Durdu, B., Batirel, A., Hakyemez, I.N., Cetin, B., et al. Colistin nephrotoxicity increases with age. Scand J Infect Dis 46 (2014), 678–685.
14. [14] Gauthier, T.P., Wolowich, W.R., Reddy, A., Cano, E., Abbo, L., Smith, L.B., Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother 56 (2012), 2392–2396 Erratum in: Antimicrob Agents Chemother 2012;56:3473.
15. [15] Doshi, N.M., Mount, K.L., Murphy, C.V., Nephrotoxicity associated with intravenous colistin in critically ill patients. Pharmacotherapy 31 (2011), 1257–1264.
16. [16] Kubin, C.J., Ellman, T.M., Phadke, V., Haynes, L.J., Calfee, D.P., Yin, M.T., Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect 65 (2012), 80–87.
17. [17] Pogue, J.M., Lee, J., Marchaim, D., Yee, V., Zhao, J.J., Chopra, T., et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 53 (2011), 879–884.
18. [18] Kim, J., Lee, K.H., Yoo, S., Pai, H., Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents 34 (2009), 434–438.
19. [19] Dubrovskaya, Y., Prasad, N., Lee, Y., Esaian, D., Figueroa, D.A., Tam, V.H., Risk factors for nephrotoxicity onset associated with polymyxin B therapy. J Antimicrob Chemother 70 (2015), 1903–1907.
20. [20] Tuon, F.F., Rigatto, M.H., Lopes, C.K., Kamei, L.K., Rocha, J.L., Zavascki, A.P., Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 43 (2014), 349–352.
21. [21] Elias, L.S., Konzen, D., Krebs, J.M., Zavascki, A.P., The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother 65 (2010), 2231–2237.
22. [22] Sorli, L., Luque, S., Grau, S., Berenguer, N., Segura, C., Montero, M.M., et al. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective, observational cohort study. BMC Infect Dis, 13, 2013, 380.
23. [23] Garonzik, S.M., Li, J., Thamlikitkul, V., Paterson, D.L., Shoham, S., Jacob, J., et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55 (2011), 3284–3294.
24. [24] Forrest, A., Silveira, F.P., Thamlikitkul, V., Garonzik, S.M., Mandragos, K., Shoham, S., et al. Toxicodynamics (TD) for colistin-associated changes in creatinine clearance (CLcr). Fifty-fourth interscience conference of antimicrobial agents and chemotherapy (ICAAC); 5–9 September 2014; Washington, DC, 2014, ASM Press, Washington, DC [abstract A-038a].
25. [25] Ortwine, J.K., Kaye, K.S., Li, J., Pogue, J.M., Colistin: understanding and applying recent pharmacokinetic advances. Pharmacotherapy 35 (2015), 11–16.
26. [26] Oliveira, M.S., Prado, G.V., Costa, S.F., Grinbaum, R.S., Levin, A.S., Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Diagn Microbiol Infect Dis 65 (2009), 431–434.
27. [27] Akajagbor, D.S., Wilson, S.L., Shere-Wolfe, K.D., Dakum, P., Charurat, M.E., Gilliam, B.L., Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis 57 (2013), 1300–1303.
28. [28] Phe, K., Lee, Y., McDaneld, P.M., Prasad, N., Yin, T., Figueroa, D.A., et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother 58 (2014), 2740–2746.
29. [29] Rigatto, M.H., Oliveira, M.S., Perdigão-Neto, L.V., Levin, A.S., Carrilho, C.M., Tanita, M.T., et al. Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B. Antimicrob Agents Chemother 60 (2016), 2443–2449.
30. [30] Abdelraouf, K., Chang, K.T., Yin, T., Hu, M., Tam, V.H., Uptake of polymyxin B into renal cells. Antimicrob Agents Chemother 58 (2014), 4200–4202.
31. [31] Plachouras, D., Karvanen, M., Friberg, L.E., Papadomichelakis, E., Antoniadou, A., Tsangaris, I., et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob Agents Chemother 53 (2008), 3430–3436.
32. [32] Abdelraouf, K., Braggs, K.H., Yin, T., Truong, L.D., Hu, M., Tam, V.H., Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother 56 (2012), 4625–4629.
33. [33] Yousef, J.M., Chen, G., Hill, P.A., Nation, R.L., Li, J., Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. J Antimicrob Chemother 67 (2012), 452–459.
34. [34] Sirijatuphat, R., Limmahakhun, S., Sirivatanuksorn, V., Nation, R.L., Li, J., Thamlikitkul, V., Preliminary clinical study of the effect of ascorbic acid on colistin-associated nephrotoxicity. Antimicrob Agents Chemother 59 (2015), 3224–3232.
35. [35] Dalfino, L., Puntillo, F., Ondok, M.J., Mosca, A., Monno, R., Coppolecchia, S., et al. Colistin-associated acute kidney injury in severely ill patients: a step toward a better renal care? A prospective cohort study. Clin Infect Dis 61 (2015), 1771–1777.
36. [36] Sandri, A.M., Landersdorfer, C.B., Jacob, J., Boniatti, M.M., Dalarosa, M.G., Falci, D.R., et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 57 (2013), 524–531.
37. [37] Ni, W., Shao, X., Di, X., Cui, J., Wang, R., Liu, Y., In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis. Int J Antimicrob Agents 45 (2015), 8–18.